Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPIDe-2: Extension Study of Deucrictibant for Acute Treatment of Hereditary Angioedema Attacks
NCT05396105Phase 3Enrolling by invitation
- Sponsor
- Pharvaris
- Start
- Dec 2022
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 24
01
Overview
A Phase 3 trial of deucrictibant in hereditary angioedema (HAE), sponsored by Pharvaris. Started Dec 2022; status: enrolling by invitation.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT05396105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05396105.